Equity Profile

MLYS

Mineralys Therapeutics, Inc.

Health CareBiotechnology$2.1B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for various health conditions....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to generate sales and expand its market presence, crucial for investor confidence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MLYS Q2-2026 Earnings Preview

Context

Company Snapshot

Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for various health conditions. Operating in the healthcare sector, it aims to address significant medical needs through its research and development efforts.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+6.74%

Avg Stock Reaction

+5.24%

Last Quarter Recap

In Q1-2026, Mineralys reported an EPS of -$0.47, beating estimates by 7.3%. The stock reacted positively, gaining 2.87% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, hoping for continued improvements in EPS and insights into revenue growth.

Bull Case

If Mineralys can maintain its trend of beating EPS estimates, it could signal strong operational performance and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's history of beating EPS estimates, this figure will be critical in shaping investor sentiment.

What insights can management provide regarding revenue growth and R&D expenses?

Understanding these metrics will help investors gauge the company's future potential and operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Mineralys to exceed EPS expectations based on historical performance trends.

Supporting Evidence

Mineralys has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.

The options market is pricing in a significant move, suggesting that traders expect more volatility than what has been typical.

Insider selling could indicate a lack of confidence in the near-term outlook, which may not align with the company's historical performance.

Key Risk

If EPS comes in worse than -$0.50, it could significantly shift market sentiment and validate bearish concerns.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to sustain its positive EPS surprises against the backdrop of its growth strategy.

Bull Confirmed If

An EPS of -$0.40 or better would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS worse than -$0.50 could confirm the bear case, suggesting potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±28.09%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant potential price movement, suggesting that investors expect volatility around the earnings report.

Options are pricing ±28.1% while MLYS has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

60.3%

Calls (863K)P/C Ratio: 2.39Puts (188K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.0M

38,722 sh

2 insiders

Net

$1.0M

Net selling

Most Active Insiders· 5 open-market trades

Chief Medical OfficerRodman David Malcom
$621,120.23

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mineralys beats expectations, history suggests a potential stock increase of around 5.22%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical data suggesting an average drop of around 5.29%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the company's product pipeline and upcoming clinical trials.
2Management's commentary on cost management and R&D spending.
3Insights into market demand for their products and potential revenue streams.
4Any guidance on future earnings expectations or strategic initiatives.
5Details on competitive positioning within the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative treatments for various health conditions....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to generate sales and expand its market presence, crucial for investor confidence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MLYS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+6.74%

Avg Stock Reaction

+5.24%

Last Quarter Recap

In Q1-2026, Mineralys reported an EPS of -$0.47, beating estimates by 7.3%. The stock reacted positively, gaining 2.87% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, hoping for continued improvements in EPS and insights into revenue growth.

Bull Case

If Mineralys can maintain its trend of beating EPS estimates, it could signal strong operational performance and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a significant drop in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's history of beating EPS estimates, this figure will be critical in shaping investor sentiment.

What insights can management provide regarding revenue growth and R&D expenses?

Understanding these metrics will help investors gauge the company's future potential and operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Mineralys to exceed EPS expectations based on historical performance trends.

Supporting Evidence

Mineralys has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.

The options market is pricing in a significant move, suggesting that traders expect more volatility than what has been typical.

Insider selling could indicate a lack of confidence in the near-term outlook, which may not align with the company's historical performance.

Key Risk

If EPS comes in worse than -$0.50, it could significantly shift market sentiment and validate bearish concerns.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to sustain its positive EPS surprises against the backdrop of its growth strategy.

Bull Confirmed If

An EPS of -$0.40 or better would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS worse than -$0.50 could confirm the bear case, suggesting potential issues in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±28.09%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant potential price movement, suggesting that investors expect volatility around the earnings report.

Options are pricing ±28.1% while MLYS has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

60.3%

Calls (863K)P/C Ratio: 2.39Puts (188K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.0M

38,722 sh

2 insiders

Net

$1.0M

Net selling

Most Active Insiders· 5 open-market trades

Chief Medical OfficerRodman David Malcom
$621,120.23

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mineralys beats expectations, history suggests a potential stock increase of around 5.22%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical data suggesting an average drop of around 5.29%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the company's product pipeline and upcoming clinical trials.
2Management's commentary on cost management and R&D spending.
3Insights into market demand for their products and potential revenue streams.
4Any guidance on future earnings expectations or strategic initiatives.
5Details on competitive positioning within the biotechnology sector.